These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34151687)

  • 21. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with
    Martínez-Losada C; Serrano-López J; Serrano-López J; Noguera NI; Garza E; Piredda L; Lavorgna S; Consalvo MAI; Ottone T; Alfonso V; Peinado JR; Garcia-Ortiz MV; Morales-Ruiz T; Jérez A; Hurtado AM; Montesinos P; Cervera J; Such E; Ibañez M; Sempere A; Sanz MÁ; Lo-Coco F; Sánchez-García J
    Haematologica; 2018 Sep; 103(9):e400-e403. PubMed ID: 29622659
    [No Abstract]   [Full Text] [Related]  

  • 23. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
    Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
    Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
    J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular remission and response patterns in patients with mutant-
    Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
    Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
    Moore DC; Nelson V; Muslimani A
    Ann Hematol; 2021 Dec; 100(12):3053-3055. PubMed ID: 33001279
    [No Abstract]   [Full Text] [Related]  

  • 27. Enasidenib: First Global Approval.
    Kim ES
    Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In brief: Two new drugs for AML.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
    [No Abstract]   [Full Text] [Related]  

  • 29. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo acute myeloid leukemia with Philadelphia chromosome (BCR-ABL) and inversion 16 (CBFB-MYH11): report of two cases and review of the literature.
    Roth CG; Contis L; Gupta S; Agha M; Safyan E
    Leuk Lymphoma; 2011 Mar; 52(3):531-5. PubMed ID: 21281226
    [No Abstract]   [Full Text] [Related]  

  • 33. Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia.
    Patel SA
    JAMA Oncol; 2018 Aug; 4(8):1110-1111. PubMed ID: 29346477
    [No Abstract]   [Full Text] [Related]  

  • 34. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.
    Gong Z; Xu ML; Chen M; Cui W; Kantarjian HM; Cortes JE; Zhou T; Tang G; Wang W; Medeiros LJ; Hu S
    Am J Hematol; 2019 Oct; 94(10):E256-E259. PubMed ID: 31273842
    [No Abstract]   [Full Text] [Related]  

  • 35. Clonal evolution with acquisition of
    Thakral B; Daver N; Tang Z; Patel KP; Ok CY; Loghavi S; Khoury JD; Alotaibi AS; Konopleva M; Yilmaz M; Medeiros LJ
    Leuk Lymphoma; 2020 Dec; 61(13):3243-3246. PubMed ID: 32696696
    [No Abstract]   [Full Text] [Related]  

  • 36. Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia.
    Quintás-Cardama A; Gibbons DL; Cortes J; Bobadilla D; Slovak ML; Kantarjian H; Abruzzo LV
    Leukemia; 2008 Apr; 22(4):877-8. PubMed ID: 17928880
    [No Abstract]   [Full Text] [Related]  

  • 37. Coexistence of inversion 16 and the Philadelphia chromosome in patients with acute myelogenous leukemia.
    Siddiqui AD; Sheikh ZS; Liu D; Seiter K
    Leuk Lymphoma; 2002 May; 43(5):1137-40. PubMed ID: 12148898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lytic bone disease as the presenting feature of Philadelphia-positive, derivative chromosome 7 myelodysplasia progressing to acute myeloid leukaemia.
    Tucker D; Hamilton MS; Kerr JP; Wickham C; Hunter H
    Gene; 2013 Feb; 515(1):239. PubMed ID: 23431568
    [No Abstract]   [Full Text] [Related]  

  • 40. Human leukocyte antigen-DR negative de novo acute myeloid leukemia with Philadelphia chromosome.
    Inaba T; Nishimura H; Saito J; Yamane Y; Nakatani T; Yamamoto M; Uchiyama H; Fujita N
    Int J Hematol; 2008 Dec; 88(5):602-605. PubMed ID: 19034612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.